Biome Australia Limited (ASX:BIO) has released its Q2 FY26 trading update, reporting record quarterly and half-year sales. The update outlines continued revenue growth across the December quarter and first half of FY26, driven by increased demand for the Company’s evidence-based probiotic products across domestic …
In 2025, select ASX-listed health care stocks recorded gains while the broader S&P/ASX 200 Health Care index declined 25.4% over the year. 4DMedical Limited rose 743.8% year-to-date, and Racura Oncology increased 99.3%. These movements reflect differences in individual company performance within the Australian health …
Telix Pharmaceuticals Limited (ASX:TLX) has released an update on its precision medicine portfolio, outlining developments related to its prostate cancer imaging agent in China and regulatory interactions with the U.S. Food and Drug Administration (FDA) for two diagnostic candidates.
4DMedical Limited (ASX:4DX) has announced that Cleveland Clinic has entered into a commercial arrangement for the clinical use of its CT:VQ™ respiratory imaging technology. The agreement allows for an initial one-month introductory pricing period, designed to support integration into clinical workflows, after which full …
4DMedical Limited (ASX:4DX) has received regulatory approval from Health Canada for its CT:VQ™ technology, clearing the way for commercial use across Canada. The approval classifies CT:VQ™ as a Class II Medical Device under the Medical Devices Directorate framework. This decision expands the company’s regulatory …
4DMedical Limited (ASX:4DX) announced it has finalised an optionunderwritingagreement with Bell Potter Securities Limited to fully underwrite all remaining 4DXO listed options on issue. These options, exercisable at AUD 1.365 each, are due to expire at 5:00pm AEDT on 31 December 2025.
EBR Systems, Inc. (ASX:EBR) announced the successful first enrolment and implant of its WiSE® System in the Totally Leadless Cardiac Resynchronisation Therapy (TLC-AU) study. The first procedure was carried out on 11 December at the Princess Alexandra Hospital in Brisbane by electrophysiologist Dr Paul …
Mayne Pharma Group Limited (ASX:MYX) has terminated the Scheme Implementation Deed (SID) with Cosette. The termination follows the company’s 3 December 2025 notice of intention to terminate, which outlined Cosette’s material breaches of the SID. These breaches continued for five business days, prompting Mayne …
Race Oncology Limited (ASX:RAC) has completed a privateplacementraising AUD 3.22m to finance the HARNESS-1 Phase 1a/b non-small cell lung cancer trial. The trial will investigate RC220 in combination with Tagrisso® (osimertinib).
Immutep Limited (ASX:IMM) and Dr. Reddy’s Laboratories Ltd. have entered a strategic collaboration through their subsidiaries, Immutep SAS and Dr. Reddy’s Laboratories SA. The agreement grants Dr. Reddy’s exclusive rights to develop and commercialise Eftilagimod Alfa (Efti) in all countries outside North America, Europe, …